Arcutis Presents Infant ZORYVE Trial Results as FDA Review Continues

Arcutis Biotherapeutics presented results from the INTEGUMENT-INFANT study of ZORYVE cream 0.05% in 101 infants with mild to moderate atopic dermatitis on November 13, 2026. Caregivers reported itch improvement for 66.7% of infants within 4 hours, while the study found no serious adverse events. Arcutis is seeking approval for use in infants aged 3 to 24 months, and the FDA review has a target decision date of February 23, 2027.

The data support Arcutis's effort to expand ZORYVE's approved pediatric use beyond children aged 2 to 5 years. FDA action by February 23, 2027, will determine whether the product can be marketed for infants aged 3 to 24 months.

  • 1The trial enrolled 101 infants with mild to moderate atopic dermatitis.
  • 2Caregivers reported at least 25% itch improvement in 46.6% of infants within 10 minutes after the first application and in 66.7% after 4 hours.
  • 3The Worst Scratch Intensity Numerical Rating Scale success rate was 72.7% at the final assessment.
  • 4Mean Patient-Oriented Eczema Measure scores fell from 14.5 initially to 7.9 at Week 2 and 6.5 at Week 4.
  • 5Arcutis's supplemental New Drug Application covers infants aged 3 to 24 months and has an FDA target action date of February 23, 2027.

Sources